BridgeBio Oncology Therapeutics, Inc. (BBOT) — Cash Flow Quality Index
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Cash Flow Quality Index of -3.48x as of December 2025. Operating cash flow of $-42.23 Million is below net income of $12.12 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore BBOT total asset value for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BridgeBio Oncology Therapeutics, Inc. Cash Flow Quality Index (2024–2024)
Historical Cash Flow Quality Index for BridgeBio Oncology Therapeutics, Inc. across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check BridgeBio Oncology Therapeutics, Inc. tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for BridgeBio Oncology Therapeutics, Inc. (2024–2024)
Year-by-year earnings quality comparison for BridgeBio Oncology Therapeutics, Inc.. For live market cap and the full company financial profile, see BridgeBio Oncology Therapeutics, Inc. market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -0.10x | $-763.82K | $7.60 Million | — |